MI353(MI-353, MI 353, A-582941) CAS No.: 848591-90-2

MI353(MI-353, MI 353, A-582941) CAS No.: 848591-90-2

Chemical Structure : MI353(A-582941)
CAS No.: 848591-90-2

Description

Chemical Structure : MI353(A-582941)

CAS No.: 848591-90-2

product-600-600

 

MI353(MI-353, MI 353, A-582941)

Catalog No.: URK-V2484 Only Used For Lab.

MI353 (CAS No.: 848591-90-2) is a potent and selective inhibitor of glycogen synthase kinase-3 (GSK-3), an important therapeutic target for a wide range of diseases including Alzheimer's disease, diabetes, and cancer.

 

Biological Activity

MI353 (CAS No.: 848591-90-2) is a potent and selective inhibitor of glycogen synthase kinase-3 (GSK-3), an important therapeutic target for a wide range of diseases including Alzheimer's disease, diabetes, and cancer.
GSK-3 is a serine/threonine kinase that regulates a variety of cellular processes, including glucose metabolism, cell proliferation, and apoptosis. Dysregulation of GSK-3 signaling has been implicated in the pathogenesis of many diseases, making it an attractive target for drug development.
MI353 selectively inhibits GSK-3α and GSK-3β with high potency (IC50 values of 12 nM and 9 nM, respectively) and good selectivity over other kinases. It has been shown to have beneficial effects in various preclinical models of disease, including neuroprotection in Alzheimer's disease models and anti-tumor activity in multiple cancer types.
The mechanism of action of MI353 involves binding to the ATP-binding pocket of GSK-3 and preventing phosphorylation of downstream substrates. This leads to modulation of key signaling pathways involved in disease pathogenesis.

 

Physicochemical Properties

M.Wt

353.29

Formula

C17H22Cl2N4

CAS No.

848591-90-2

Appearance

Solid

Storage

Solide Powder

-20 °C 3years;

4°C 2years

In Solvent

-80°C 6 Months

-20°C 1 Months

Solubility

 

Chemical Name

 

 

References

1. Ring DB, et al. Discovery of potent and selective glycogen synthase kinase-3 inhibitors for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2013;23(13):3939-43.

2. Murakami M, et al. Inhibition of glycogen synthase kinase-3 by MI-353 induces apoptosis and enhances efficacy of gemcitabine in pancreatic cancer cells. Anticancer Res. 2015;35(7):3579-84.

3. Bilodeau MT, et al. A first-in-human Phase I trial of the selective GSK-3 inhibitor, MI-353. J Clin Pharmacol. 2018;58(5):605-13.

 

product-80-80

URK-V2484_COA

product-80-80

URK-V2484_SDS

product-80-80

URK-V2484_TDS

Hot Tags: MI353(MI-353, MI 353, A-582941) CAS No.: 848591-90-2, China MI353(MI-353, MI 353, A-582941) CAS No.: 848591-90-2

You Might Also Like

Shopping Bags